A clinical evaluation of indium‐111 bleomycin as a tumor‐imaging agent

In an evaluation of indium‐111‐bleomycin as a tumor‐imaging agent, 357 whole‐body tumor scans were performed in 293 patients. Of 246 studies performed in patients with a variety of active solid tumors, 218 (89%) were true‐positive studies and 28 (11%) were false‐negative. Of 69 scans in patients thought to be free of tumor after therapy, 32 (46%) were false‐positive studies and 37 (54%) were true‐negative. The true‐positive rates by major tumor type were: adenocarcinoma of gastrointestinal tract origin (95%), lymphoma (88%), melanoma (87%), sarcomas (82%), lung (77%), breast (77%), childhood tumors (71%), gynecologic tumors (70%), and genitourinary tumors (68%). Soft tissue and lymphatic sites of tumor, both above and below the diaphragm, were easily visualized, whereas hepatic and bone marrow sites of involvement were less easily discerned. False‐positive uptake with 111In‐bleomycin was noted in lungs (6%), gut (3%), mediastinum (2%), normal breast tissue (0.8%), and in occasional inflammatory lesions. In 19 patients with multiple myeloma or leukemia, a pattern of diminished bone marrow uptake associated with abnormal accumulation of 111In‐bleomycin in extramedullary sites of involvement was the rule. In another 23 patients in whom scans were performed because an occult tumor was suspected, scanning did not lead to specific diagnosis of tumor in a single instance. We conclude that 111In‐bleomycin is a safe, effective, and useful new tumor‐imaging agent in the initial staging and followup of patients with a variety of solid tumors. Significant advantages of this agent over other currently available radiopharmaceuticals include: A) a broader spectrum of tumors taking up the radio‐pharmaceutical, and B) generally better delineation of abdominal and pelvic disease due to lack of interference from gut uptake.